Citigroup, Deutsche Bank Securities, Leerink Swann
BMO Capital Markets, Baird
For IPO Boutique's "scale of 1 to 5" BUY rating on Tesaro, and our comprehensive analysis, click the "Buy Market Research" link.
About Tesaro (adapted from Tesaro prospectus): Tesaro is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. They have in-licensed and are currently developing two product candidates, rolapitant and TSR-011. They intend to continue to identify, acquire, develop and commercialize cancer therapeutics and oncology supportive care products that are safer and more effective than existing treatments.
This description is adapted from Tesaro prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as Tesaro "TSRO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.